San Diego-primarily based Viking Therapeutics marked alone as a serious competitor within the weight loss drug current market in February just after revealing promising data from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in March the c